Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms

References

• Abdelbary AM, El-Dessoukey AA, Massoud AM, et al. Combined vaginal pelvic floor electrical stimulation (PFS) and local vaginal estrogen for treatment of overactive bladder (OAB) in perimenopausal females. Randomized Controlled Trial (RCT). Urology 2015;86:482–6
   PubMed Web of Science ®Google Scholar
• Robinson D, Cardozo L, Milsom I, et al. Oestrogens and overactive bladder. Neurourol Urodyn 2014;33:1086–91
   PubMed Web of Science ®Google Scholar
• Robinson D, Toozs-Hobson P, Cardozo L. The effect of hormones on the lower urinary tract. Menopause Int 2013;19:155
   PubMedGoogle Scholar
• Lüthje P, Brauner H, Ramos N, et al. Estrogen supports urothelial defense mechanism. Sci Trans Med 2013;5:190ra80
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass ML. Vulvovaginal atrophy terminology consensus conference panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Climacteric 2014;17:557–63
   PubMed Web of Science ®Google Scholar
• Palacios S, Mej A, Neyro JL. Treatment of the genitourinary syndrome of menopause. Climacteric 2015;8:23–9
   Web of Science ®Google Scholar
• Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2016;8:CD001500
   Google Scholar
• Nappi RE, Palacios S, Particco M, Panay N. Results of the European REVIVE (REal women’s VIew of treatment options for menopausal Vulvar/Vaginal changEs) survey. Maturitas 2015;81:106–83
   Google Scholar
• Goldstein SR, Bachmann GA, Koninckx PR, et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014;17:173–82
   PubMed Web of Science ®Google Scholar
• Bondi C, Ferrero S, Scala C, et al. Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause. Expert Opin Drug Metabol Toxicol 2016;12:1233–46
   PubMed Web of Science ®Google Scholar
• Visco AG, Wei JT, McClure LA, et al. Effects of examination technique modifications on pelvic organ prolapse quantification (POP-Q) results. Int Urogynecol J Pelvic Floor Dysfunct 2003;14:136–40
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Perniola GD, Donato V. Severe pelvic organ prolapse treated by vaginal native tissue repair: long-term analysis of outcomes in 146 patients. Arch Gynecol Obstet 2017;295:917–22
   PubMed Web of Science ®Google Scholar
• Rachaneni S, McCooty S, Middleton LJ, et al. Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation. Health Tecnol Assess 2016;20:1–150
   PubMed Web of Science ®Google Scholar
• Shumaker S, Wyman JP, Uebersax JS, et al. Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Qual Life Res 1994;3:291–306
   PubMed Web of Science ®Google Scholar
• Coyne K, Schmier J, Hunt T, et al. Developing a specific HRQL instrument for overactive bladder. Value Health 2000;3:141
   Google Scholar
• Bachman G. Urogenital ageing: an old problem newly recognized. Maturitas 1995;22:S1–5
   PubMed Web of Science ®Google Scholar
• Lucas MG, Bosch RJ, Burkhard FC, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol 2012;62:1130–42
   PubMed Web of Science ®Google Scholar
• Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46–53
   PubMed Web of Science ®Google Scholar
• Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011;65:567–85
   PubMed Web of Science ®Google Scholar
• Lüthje P, Hirschberg A, Brauner A. Estrogenic action on innate defense mechanisms in the urinary tract. Maturitas 2013;77:32–6
   PubMed Web of Science ®Google Scholar
• Perino A, Calligaro A, Forlani F, et al. Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser. Maturitas 2015;80:296–301
   PubMed Web of Science ®Google Scholar
• Zerbinati N, Serati M, Origoni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Laser Med Sci 2015;30:429–36
   PubMed Web of Science ®Google Scholar
• Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric 2014;17:363–9
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Komi JO. The Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17:480–6
   PubMed Web of Science ®Google Scholar
• Portman DJ, Bachmann GA, Simon JA. The Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20:623–30
   PubMed Web of Science ®Google Scholar
• Portman D, Palacios S, Nappi RE, Mueck AO. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas 2014;78:91–8
   PubMed Web of Science ®Google Scholar
• David FA, Carr BR, Pinkerton JV, et al. Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence. Menopause 2015;22:786–96
   PubMed Web of Science ®Google Scholar
• Constantine G, Graham S, Portman DJ, et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric 2015;18:226–32
   PubMed Web of Science ®Google Scholar
• Oelke M, Khullar V, Wijkstra H. Review on ultrasound measurement of bladder or detrusor wall thickness in women: techniques, diagnostic utility, and use in clinical trials. World J Urol 2013;31:1093–104
   PubMed Web of Science ®Google Scholar
• Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol 2001;77:271–9
   PubMed Web of Science ®Google Scholar
• Lüthje P, Hirschbergb AL, Brauner A. Estrogenic action on innate defense mechanisms in the urinary tract. Maturitas 2014;77:32–6
   PubMed Web of Science ®Google Scholar